Hypertension is associated with nitric oxide (NO) deficiency and increased reactive oxygen species. 1 Reactive oxygen species can activate nuclear factor-kappa B (NFκB) via redox-sensitive signal transduction. NFκB is a general transcription factor for pro-inflammatory pathways. 2 Systemic and renal inflammation has been proposed to be an underlying mechanism which drives both hypertension development and renal injury. 3 Both inflammation and upregulation of NFκB activation are already present in kidneys of 3-week-old pre-hypertensive spontaneously hypertensive rats (SHR), and NFκB inhibition can prevent the development of hypertension. 4 Previously, we found in SHR that perinatal interventions, which manipulate the NO/reactive oxygen species balance, can alleviate the development of hypertension in later life. 5-7 Therefore, it is conceivable that inhibiting NFκB sensitive pro-inflammatory pathways suppresses or prevents development of the hypertensive phenotype. Indeed, we found that perinatal treatment with an NFκB inhibitor (pyrrolidine di thio carbamate, PDTC) to SHR dams during pregnancy and lactation, abrogated development of hypertension in both female and male offspring, and lowered urinary excretion of lipid peroxides long after treatment was stopped. 8 In the current study we used the fawn-hooded hypertensive (FHH) rat, in order to extend these observations beyond the SHR model. The FHH is a genetic model of hypertension with progressive renal injury characterized by mild systemic BACKGROUND Inhibition of transcription factor nuclear factor-kappa B (NFκB) is beneficial in various models of hypertension and renal disease. We hypothesized first that NFκB inhibition during renal development ameliorates hereditary hypertensive renal disease and next whether this was mediated via suppression of peroxisome proliferator-activated receptor (PPAR)γ coactivator 1α (PGC-1α).
hypertension, marked proteinuria and glomerulosclerosis. [9] [10] [11] Early initiation of antihypertensive treatment protects the FHH kidney more effectively than late initiation despite a similar antihypertensive effect. 12 Perinatal molsidomine, a tolerance-free NO donor, persistently decreased blood pressure and ameliorated renal injury in male and female FHH offspring. 13 We hypothesized that NFκB activation is an early event that precedes the development of hypertension and renal injury in FHH, and that perinatal inhibition of NFκB with PDTC ameliorates hypertension and is renoprotective in male and female FHH offspring. First, we studied NFκB activation in newborn FHH as well as direct and long-term effects on the development of hypertension and renal damage of perinatal treatment with PDTC in female and male FHH offspring. Next, microarray studies were employed to screen the genome in the kidneys of newborn, young, and adult FHH for genes persistently regulated in response to perinatal NFkB inhibition. Finally, since this analysis revealed that peroxisome proliferator-activated receptor (PPAR)γ coactivator 1α (PGC-1α) gene expression was consistently increased in both genders and at all ages during and after perinatal PDTC treatment, we investigated the effects of perinatal treatment of FHH with the PPARγ agonist, pioglitazone (Pio) on blood pressure, and renal damage (proteinuria, histology) on male and female offspring.
METHODS

Animals
FHH rats were housed at 22 °C, humidity 60% and exposed to a 12 h light/dark cycle. FHH rats were obtained from our own colony, which was derived from the original colony at Erasmus University Rotterdam (FHH/EUR) maintained by Dr A. Provoost. Normotensive Wistar-Kyoto (WKY) rats (Harlan-Olac, Oxon, UK) were used as breeders exclusively to provide additional control pups for NFκB activity as measured by p65 levels. Sentinel animals were housed under the same conditions and regularly monitored for infection by nematodes and pathogenic bacteria and antibodies for rodent viral pathogens (International Council for Laboratory Animal Science, Nijmegen, The Netherlands). The Utrecht University Board for studies in experimental animals approved the both PDTC and Pio protocols.
Treatment protocol, chronic follow-up, and terminal protocol
PDTC: From day 7 of gestation, dams and their offspring received either tap water (FHH con) or PDTC in drinking water (150 mg/l) until 4 weeks of age (FHH PDTC). At 2 days of age litters were culled to a maximum of 8 pups/litter and at 2 weeks of age to a maximum of 6 pups/litter in order to standardize drug intake during lactation. Kidneys of culled pups were used for renal NFκB activity and NFκB-sensitive gene expression studies (see below). Age-and sex-matched WKY pups were also sacrificed at the same age for measurement of renal NFκB activity. In each subgroup (FHH or WKY, male or female, 2 day-or 2 week old) 5 pups were used from 5 different litters. The remaining FHH pups were weaned at 4 week and used for chronic follow-up until 36 weeks in males and 42 weeks in females (see protocol below).
Pioglitazone: During the study with Pio we followed the same treatment protocol. Starting at day 7 of gestation and until 4 weeks of age, FHH dams and their offspring received powdered chow (FHH Con) or Pio (10 mg/kg body weight of the dam; FHH Pio) mixed with the powdered chow. At 2 days of age litters were culled to a maximum of 8 pups/ litter and at 2 weeks of age to a maximum of 6 pups/litter in order to standardize Pio intake during lactation. Livers of culled pups at those 2 ages were used for PPARγ-sensitive gene expression (see below). The remaining FHH pups were weaned at 4 weeks and used for chronic follow-up until 42 weeks (see protocol below).
At 10 weeks of age, 10 FHH Con and 10 FHH Pio rats were used for glomerular counting, as described below. Standard protocols and procedures for sample collection were followed during the terminal experiments with the remaining FHH Con (n = 14) and FHH Pio (n = 15) male and female rats at 42 weeks of age as described below.
Renal NFκB activity in pups: Whole snap-frozen kidneys from male and female FHH and WKY pups (2 day and 2 week old, respectively) were homogenized and the extracts were isolated using the Nuclear Extract Kit (Active Motif, Rixensart, Belgium) according to the protocol of the supplier. Concentration of protein extracts was determined by the Bradford method (BioRad Laboratories, Veenendaal, The Netherlands). The NFκB component p65 was measured using TransAM™ NFκB p65 (Active Motif). A dilution range of recombinant NFκB p65 protein (Active Motif) was used to quantify p65 in the samples. To confirm linearity of the dilution range (correlation r 2 = 0.99), the positive control cell extract included in the TransAm kit and several random samples were also diluted. All samples were measured in duplicate. The relative p65 content in nuclear extract was determined by comparing the p65 to protein concentration ratio of the same sample.
Chronic follow-up: Systolic blood pressure (SBP) was measured regularly from 4 weeks of age by tail-cuff. After SBP measurement rats were placed in metabolism cages without food for 24 hours, but with free access to tap water with 2% glucose, for determination of urinary excretion of protein, measured with Coomassie blue (Bradford). 14 In the PDTC experiment female, offspring were studied till 42 weeks and male offspring till 36 weeks. Females were followed 6 weeks longer because male FHH generally develop proteinuria sooner than female FHH. 13 In the Pio experiment all offspring were studied till 42 weeks.
Terminal protocol: On the day of the experiment surgery was performed as described. [15] [16] [17] In short, rats from the PDTC experiment were anesthetized with intraperitoneal pentobarbital sodium 60 mg/kg body weight. Rats from the Pio experiment were anesthetized through inhalation of isoflurane at a dose of 2%. 16 This discrepancy was dictated by altered ethical board requirements. Renal function was assessed through p-amino hippuric acid and inulin clearances. We used p-amino hippuric acid clearance to determine the renal plasma flow (RPF) and inulin clearance to determine glomerular filtration rate (GFR). 13, 16 Renal blood flow (RBF) was calculated as RPF/(1-hematocrit).
Microarray screening for genes in the kidney responsive to NFkB inhibition
Detailed methodology for the microarray approach can be found in the "Supplementary Data. " Kidneys from 2-day-, 2-week-, and adult FHH of both genders were used (n = 5/ group). Data processing was performed as described. 18 The microarray data set was submitted as MIAME through NCBI's Gene Expression Omnibus (http://www.ncbi.nlm. nih.gov/geo/) under accession number GSE57066.
Real-time quantitative polymerase chain reaction
To determine the direct effects of maternal treatment with an NFκB inhibitor or a PPARγ agonist on mRNA expression of NFκB-or PPARγ-target genes, RNA was isolated from kidney and liver of 2-day-and 2-week-old offspring, reverse transcribed to cDNA and quantified using real-time quantitative polymerase chain reaction (qPCR). Real-time qPCR was performed on a ViiA 7 Real-Time PCR System (Applied Biosystems, Foster City, CA). The following TaqMan Gene Expression Assays (Applied Biosystems) were used: NFκB-target genes: PGC-1α (Rn01453111_m1), PPARγ-target genes: Adiponectin (Rn00595250_m1), Sirtuin 6 (Rn01408250_g1), FOXO-1 (Rn01494868_m1), and CISD-1 (Rn01429087_m1); and housekeeping genes: β-actin (Rn00667869_m1) and calnexin (Rn00596877_m1). Reactions were carried out in duplicate. Cycle time (Ct) values for genes of interest were normalized for mean Ct-values of calnexin and β-actin, which we previously determined to be the 2 most stable housekeeping genes across all groups using Normfinder (http://moma.dk/normfinder-software) and GeNorm (http://medgen.ugent.be/~jvdesomp/genorm/), and expressed using the ΔΔCt method. Hence, steady-state mRNA levels in treated FHH were expressed as % change relative to age-and gender-matched control FHH.
Morphology
At the end of each terminal experiment, the right kidney was harvested, blotted dry, weighed, snap frozen, and stored at −80 °C. Subsequently, left kidney preservation was done as described by Black et al. 19 Heparin sodium (1 unit heparin/gram body weight), to prevent clotting, and papaverine hydrochloride (1.2 mg/rat), to dilate the vasculature, were administered via femoral artery. After approximately 3 minutes the abdominal aorta was exposed and tied off above the left renal artery. Then the kidney was perfused in situ with saline before fixation with 2.5% glutaraldehyde (w/v) in 0.1 M phosphate buffer (pH 7.4) at a pressure of 10 mm Hg above measured mean arterial pressure (MAP) for approximately 3 minutes, excised, de-capsulated, and placed in 4% buffered formaldehyde.
Paraffin sections were stained with periodic acid-Schiff. Glomeruli were counted at magnification 50×, by applying a grid on randomly chosen fields, and expressed as number of glomeruli/mm 3 (n), calculated by the formula n = G/[F × A × (D + T)], were G is the number glomeruli counted, F the number of fields counted, A the grid area, D, the average glomerular tuft diameter, and T the section thickness (0.004 mm). 20 All glomeruli were counted, irrespective of any sign of injury. Fifty glomeruli were scored for the presence of sclerotic lesions. 21 We differentiated full sclerotic and partial sclerotic glomeruli and the sum of these two (sum). Glomerular and tubulo-interstitial ED-1-antigen-positive monocytes/macrophages were determined as described. 14 Paraffin sections (3 μm) of formaldehyde-fixed kidney were deparaffinized and rehydrated. Incubation with the ED-1 mouse monoclonal antibody (Serotec/Camon, Wiesbaden, Germany) demonstrated monocytes/macrophages. After application of ED-1 (dilution 1: 2,500 in phosphate-buffered saline containing 5% BSA, 0.4% sodium azide) to the slides at 22 °C for 1 hour, bound antibody was detected by the DAKO EnVision + System (prediluted peroxidase-dextran-conjugated goat anti-mouse antibody and DAB color reaction).
Statistics
Values are expressed as mean ± SEM. Data were compared with unpaired t-test, one-way analysis of variance and twoway analysis of variance for repeated measurements where appropriate. Proteinuria data were log 10 transformed to achieve a normal distribution. The Student-Newman-Keuls test was used as a post hoc test (P < 0.05). Significance of differentially expressed genes between FHH PDTC vs. FHH Con was determined by Cyber T test using log 2 transformed and quantile normalized data (P < 0.05).
RESULTS
Perinatal NFκB inhibition
NFκB activity in pups: Renal levels of NFκB component p65 (mg/g protein) were increased in both female and male 2-day-old FHH pups when compared to age-and gendermatched WKY pups (on average +50% and +200% in females and males, respectively; both P < 0.01, Figure 1 ). Maternal treatment with PDTC in FHH completely prevented this increase in both females and males (both P < 0.01). At 2 weeks of age there were no longer differences in renal p65 levels between FHH and WKY and there was also no effect of PDTC in FHH. Development: All litters were carried to full gestation and litter size was not affected by PDTC (FHH Con: 7 ± 1 pups/ litter, FHH PDTC: 7 ± 1 pups/litter). Perinatal PDTC (until 4 weeks) resulted in a mild but significant decrease in body weight from 12 weeks in females and males until sacrifice (Supplementary Figure S1 and Table S1 ).
Blood pressure, proteinuria, glomerular injury, and glomerular density: Perinatal PDTC treatment reduced SBP at 4 weeks in females and males and had a pronounced long-term antihypertensive effect resulting in a persistently reduced SBP by 20-30 mm Hg in both female and male FHH until sacrifice (P < 0.001, Figure 2 ). Perinatal PDTC reduced proteinuria from 20 weeks onwards in male FHH and at 28 and 36 weeks in female FHH ( Figure 3 ) and also reduced glomerulosclerosis at the end of the follow-up period. Full sclerotic glomeruli and the sum of partial and full sclerotic glomeruli were significantly decreased by perinatal PDTC in both female (P < 0.05) and male (P < 0.001) FHH ( Figure 4 ). Glomerular macrophages were reduced by perinatal PDTC in males (1.4 ± 0.3 vs. 7.0 ± 1.1 ED1-positive cells/100 glomeruli, P < 0.05) as were tubulo-interstitial macrophages (0.7 ± 0.1 vs. 2.4 ± 0.5 ED1-positive cells/field, P < 0.05). Glomerular macrophages were practically absent in all females, but tubulo-interstitial macrophages were reduced by perinatal PDTC in females (0.04 ± 0.03 vs. 0.65 ± 0.30 ED1-positive cells/field, P < 0.05). Glomerular density was increased in male FHH PDTC (P < 0.001, Supplementary Figure S2 ) but not in female PDTC.
Renal hemodynamics at the end of follow-up: MAP assessed by direct femoral artery pressure measurements confirmed significantly reduced arterial pressure in both female and male FHH at the end of the follow-up period (P < 0.05 and P < 0.01, respectively; Table 1 ). Perinatal PDTC decreased GFR in female FHH (P < 0.01) and decreased GFR, RPF, and RBF in male FHH (all P < 0.05, Table 1 ).
Renal PDTC-sensitive gene expression in pups: Differential gene expression was studied with Illumina Bead Arrays in whole kidney homogenates of 2-day-, 2-week, and adult male and female FHH offspring of dams treated with PDTC in comparison to age-and sex-matched offspring of untreated FHH dams (n = 5/group). At 2 days of age the signal on the microarray of 349 genes was different in the offspring of PDTC-treated animals compared to matched offspring of untreated animals. This suggested induction of the expression of 276 genes and suppression of 73 genes in both male and female offspring. At 2 weeks of age, only 9 PDTC-sensitive genes were likewise differentially expressed, that is up (n = 7) and down (n = 2). None of these 9 genes were differentially expressed at 2 days of age. The low number of PDTC-sensitive differential gene expression as studied by microarray coincides with the absence of differences in renal NFκB component p65 at 2 weeks (Figure 1 ). In adults, 25 PDTC-sensitive genes were also differentially expressed, that is up (n = 18) and down (n = 7). None of these 25 genes were differentially expressed at 2 weeks of age.
The most consistently regulated NFκB-sensitive gene was PGC-1α (Table 2 ). This gene showed increased expression during and after PDTC treatment, although the increase was not significant at 2 weeks in males. This was confirmed by qPCR, although in this case the difference was not significant at 2 days ( Table 2) . A selection of other NFκBsensitive genes, grouped according to function, is listed in Supplementary Table S1 . Functional groups include regulation of NFκB (Nkiras1), insulin-like growth factors (IGF2 and IGFbp3), angiogenesis and nitric oxide (vascular endothelial growth factor, endothelin B receptor), and nephrogenesis (Nidogen1, Notch1, and Nephrin). Many of the other differentially expressed genes were related to cell-cell communication and extracellular matrix. Note that practically all these genes were consistently differentially upregulated by NFκB inhibition at 2 days of age. Notably, deoxyribonuclease 1 (Dnase1) was markedly down-regulated.
Perinatal PPARγ stimulation
Hepatic PPARγ activity in pups: The liver is the canonical target of PPARγ. 22, 23 Hepatic mRNA expression of PPARγ downstream genes showed increased expression of CSD-1) and SIRT-6 genes at 2-day-old FHH rats perinatally treated with Pio compared with age-matched FHH control rats. At 2 weeks the pattern shifted and we found decreased expression of AdipoQ and FOXO-1 genes after perinatal treatment with Pio (Table 3) . Development: All litters were carried to full gestation and litter size was not affected by perinatal Pio (FHH Con: 9 ± 1 pups/litter, FHH Pio 10 ± 1 pups/litter). Perinatal Pio resulted in no change in body weight in female offspring but a significant and persistent decrease in body weight from 24 weeks in male offspring (Supplementary Figure S3 ).
Weeks
Blood pressure, proteinuria, glomerular injury, and glomerular density: Perinatal Pio treatment reduced SBP at 4 weeks in females and males. However, there was no persistent longterm antihypertensive effect (Supplementary Figure S4) . Perinatal Pio had neither significant effects on proteinuria in either female or male FHH (Supplementary Figure S5) , nor was there a reduction in glomerulosclerosis in female or male Pio offspring at 42 weeks (Supplementary Figure S6) . Glomerular density at 10 and 42 weeks was unaffected by perinatal Pio (Supplementary Figure S7) .
Renal hemodynamics at the end of follow-up: MAP was also not significantly affected at the end of the follow-up period ( Table 4 ). Perinatal Pio had no effect on GFR, RPF, and RBF in female FHH but decreased GFR, RPF, and RBF in male FHH (all P < 0.05, Table 4 ). Renal vascular resistance (RVR) was unchanged in FHH Pio females but increased in FHH Pio males (P < 0.05). Note that the FHH Con data in Table 4 differ slightly from those in Table 1 , primarily due to differences in the anaesthetic regimen.
DISCUSSION
The present study addressed the question whether the previously observed induction of the pro-inflammatory transcription factor NFkB in the early life of the SHR was also present in the FHH, whether inhibiting NFkB in the perinatal situation attenuated the hypertension and renal damage in the FHH and whether this was related to depressed PPARγ. In the FHH, NFkB is induced early in life and perinatal inhibition of NFkB with PDTC indeed ameliorated the hypertension and renal injury. Gene expression analysis of the kidney cortex revealed PPARγ depression as a potential mechanism of NFkB-mediated hypertension and renal injury in the offspring. Despite sex-specific alterations in renal hemodynamics, perinatal administration of a PPARγ agonist did not ameliorate hypertension and renal damage.
Activation of redox sensitive transcription factor NFκB is associated with hypertension, with renal injury or both 2 Moreover, inhibition of NFκB with PDTC can prevent or ameliorate both hypertension and renal injury in many models. 4, [24] [25] [26] [27] [28] Previously, we documented that perinatal interventions affecting the redox balance can ameliorate hypertension in SHR. 5, 6, 29, 30 We also documented that, in FHH, a model of hypertensive renal injury 9-11 perinatal administration of an NO donor ameliorates hypertension and renal injury. 13 In the current study, we first addressed the question whether NFκB is already activated during nephrogenesis in the FHH model and whether such activation plays a role in subsequent renal disease and hypertension. We could indeed demonstrate activation of NFκB in kidneys of newborn FHH, by increased levels of p65, a component of active NFκB. 31 Activation of NFκB was not measured in adult rat because we probed effects relating to development not injury. Moreover, glomerular density was substantially increased in adult male FHH PDTC as compared to FHH Con. Perinatal NFκB inhibition persistently ameliorated the development of hypertension and proteinuria in both female and male FHH. At the end of the study GFR and glomerulosclerosis were both reduced, suggesting persistent amelioration of hyperfiltration by perinatal PDTC. In the FHH rat, prone as it is to hyperfiltration, 9, 11, 13 a similar hemodynamic response was observed after perinatal administration of a NO donor. 13 Therefore, in this model of hereditary hypertension associated renal injury, early life NFkB activation seems pivotal to develop hypertension and renal injury. Group size: 2-day FHH Con n = 10, 2-day FHH Pio n = 10, 2-week FHH Con n = 12, 2-week FHH Pio n = 9. Differential expression was determined by qPCR (% ± SEM) by t-test (*P ≤ 0.05 vs. agematched FHH Con set at 100%). Mean ± SEM.
Abbreviations: FHH, fawn-hooded hypertensive; PPAR, peroxisome proliferator-activated receptor; qPCR, quantitative polymerase chain reaction.
These initial results support a role for persistent alterations in hemodynamics after perinatal PDTC in FHH. Note that in SHR, a strain with increased RVR, 15,17 perinatal PDTC did not significantly affect GFR or RVR in either female or male offspring. 8 Proteinuria was ameliorated by perinatal PDTC in conjunction with a significant blood pressure reduction. Moreover, development of glomerular sclerosis was clearly reduced by perinatal PDTC treatment, suggesting that the less pronounced incline in proteinuria observed in FHH PDTC, represents less progressive renal injury. In FHH controls RBF and GFR were positively correlated with sclerosis. 13 Probably this illustrates low preglomerular resistance in the FHH strain, resulting in glomerular hypertension, and consequently glomerular hyperperfusion, hyperfiltration, and injury. Our current findings are compatible with the idea that perinatally inhibiting the transcription factor NFκB can prevent the development of glomerular hypertension by increasing afferent arteriolar resistance (since both GFR and RBF decrease). The reduction in macrophage infiltration was probably secondary to the reduction in glomerular proteinuria. 13 That said, the other possibility is that non-hemodynamic mechanisms related to the activation of NFkB early in life-related genes are responsible for the hypertension and renal damage in the FHH. Generally PDTC is applied as an NF-kappa B inhibitor. However, antioxidant effects have also been described, [32] [33] [34] although arguably these could be secondary to NF-kappa B inhibition. More specific "off-target" effects include Nrf2 activation leading to the induction of glutamate cysteine ligase modulatory gene expression 35 and stromelysin expression via a tyrosine kinase-AP-1 pathway. 36 Therefore, we believe that perinatal targeting of NF-kappa B by PDTC in our studies in SHR 8 and FHH (this study) should be seen as proof of principle experiments in models of genetically programmed hypertension (SHR and FHH) and renal injury (FHH), and certainly not as a direct incentive to apply PDTC in the obstetric or neonatal clinic.
Because maternal treatment with the NFκB inhibitor PDTC normalized renal levels of the NFκB component p65, we assessed NFκB-sensitive renal gene expression in the offspring. At 2 day of age, in the nephrogenic phase, NFκBsensitive renal gene expression was characterized by a pronephrogenic and angiogenic pattern. Nephrogenesis in the rat starts at embryonic day 12 and is complete at about 10 days after birth. 37 NFκB activity, that is, p65 levels, and NFκBsensitive gene expression are increased in the middle of this process in the FHH. Parallel with p65 levels, NFκB-sensitive gene expression waned at 2 weeks of age, suggesting an association between NFκB activation and nephrogenesis in FHH. Indeed, Nidogen1, Notch1, Nephrin, and vascular endothelial growth factor, genes that are known to be involved in nephrogenesis 38, 39 and angiogenesis 40 were differentially expressed at 2 days in female and male offspring. Specifically, PGC-1α was differentially expressed. This transcription factor has powerful anti-inflammatory and vasculogenic effects and is known for its stimulatory effects on all 3 PPAR's: α, β, and γ. 41, 42 Several other groups of genes of interest were identified by this discovery approach. These groups included insulin signaling, and induction of a large number of genes related to cell-cell communication and extracellular matrix ( Supplementary Table S1 ). Overall this gene expression analysis emphasized the importance of angiogenesis and nephrogenic genes and cell-cell communication and extracellular matrix. In line with the induction of nephrogenic genes is the observation of ~25% increase in glomerular density in adult male FHH treated perinatally with PDTC. Since we previously could identify candidates for perinatal treatment in SHR using differential gene expression of renal homogenates, 29, 30 in follow-up experiments we now tested whether depression of PPARγ, downstream of the transcription factor PGC-1α, could be a mediator of hypertension and renal injury in FHH rats. Perinatal treatment with the PPAR-γ agonist Pio did not persistently reduce arterial pressure, proteinuria, or glomerulosclerosis in FHH suggesting that other factors downstream of NFκB confer renal protection. Exposure of the pups to Pio was confirmed by the characteristic changes in hepatic gene expression after PPARγ agonists. 22, 23 In addition, there appeared to be a direct antihypertensive effect of Pio at 4 weeks in female and male FHH. Mild, direct antihypertensive effects of PPARγ agonists have been reported in models of genetic or induced hypertension, [43] [44] [45] [46] including perinatal low-protein diet. 47 Moreover, the late appearance (after 5-6 months of age) of reduced body weight in FHH Pio males, suggested metabolic programming. Lower body weight and improved glucose tolerance were observed after 2 weeks of Pio in a murine model of programmed obesity. 48 Interestingly, there was a reduction in hyperfiltration and hyperperfusion in the male, but not the female FHH at 42 weeks after perinatal Pio. Specifically in the male FHH, renal hemodynamic changes reflected the changes in the PDTC-treated offspring, although the 9 mm Hg decrease in MAP was not significant. The simultaneous decrease in GFR and RPF is compatible with an increase in afferent arteriolar resistance. Interestingly therefore is that both perinatal PDTC and perinatal Pio affected renal hemodynamics (although obviously this was less pronounced in Pio treated rats), yet only perinatal PDTC could dampen the development of hypertension and renal injury. This suggests that hemodynamic factors may not be the crucial link between perinatal induction of NFkB and subsequent renal damage. In future experiments, it might be interesting to further probe the PGC-1α pathway with a PPAR-β agonist. PPAR-β agonists have been shown to have antihypertensive and renoprotective effects in genetic and acquired models of hypertension. 49, 50 In conclusion, these data indicate that renal NFκB expression is enhanced in 2-day FHH and that this can be ameliorated by the NFkB inhibitor PDTC. Perinatal PDTC stimulates gene expression related to angiogenesis and nephrogenesis and has persistent antihypertensive and renoprotective effects, coinciding with less hyperfiltration. A key downstream layer seems the PGC-1α pathway, yet perinatal PPARγ stimulation did not affect hypertension and renal damage. Interestingly, renal hemodynamics effects of perinatal PPARγ and perinatal PDTC were similar in male offspring. We conclude that in the FHH rat early induction of NFkB is involved in blood pressure regulation and glomerular damage in the offspring, yet, when we tested one of the downstream genes of the PGC-1α pathway, PPARγ, the findings also pointed toward non-hemodynamic pathways for protection.
SUPPLEMENTARY MATERIAL
Supplementary materials are available at American Journal of Hypertension (http://ajh.oxfordjournals.org).
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